Effects of rosiglitazone and pioglitazone on lipoprotein metabolism in patients with Type 2 diabetes and normal lipids
- 11 May 2009
- journal article
- research article
- Published by Wiley in Diabetic Medicine
- Vol. 26 (5), 532-539
- https://doi.org/10.1111/j.1464-5491.2009.02729.x
Abstract
Previous studies have suggested that plasma lipids are affected differently by the peroxisome proliferators-activated receptor (PPAR)-gamma agonists pioglitazone and rosiglitazone. The aim of this study was to perform a quantitative lipoprotein turnover study to determine the effects of PPAR-gamma agonists on lipoprotein metabolism. Twenty-four subjects with Type 2 diabetes treated with diet and/or metformin were randomized in a double-blind study to receive 30 mg pioglitazone, 8 mg rosiglitazone or placebo once daily for 3 months. Before and after treatment, absolute secretion rate (ASR) and fractional catabolic rate (FCR) of very low-density lipoprotein (VLDL), intermediate-density lipoprotein (IDL) and low-density lipoprotein (LDL) apolipoprotein B100 were measured with a 10-h infusion of 1-13C leucine. There was a significant decrease in glycated haemoglobin (HbA(1c)) and non-esterified fatty acids with pioglitazone (P = 0.01; P = 0.02) and rosiglitazone (P = 0.04; P = 0.003), respectively, but no change in plasma triglyceride or high-density lipoprotein (HDL) cholesterol. Following rosiglitazone, there was a significant reduction in VLDL apolipoprotein B100 (apoB) ASR (P = 0.01) compared with baseline, a decrease in VLDL triglyceride/apoB (P = 0.01), an increase in LDL2 cholesterol (P = 0.02) and a decrease in LDL3 cholesterol (P = 0.02). There was a decrease in VLDL triglyceride/apoB (P = 0.04) in the pioglitazone group. There was no significant difference in change in VLDL ASR or FCR among the three groups. In patients with Type 2 diabetes and normal lipids, treatment with rosiglitazone or pioglitazone had no significant effect on lipoprotein metabolism compared with placebo.Keywords
This publication has 30 references indexed in Scilit:
- A pilot study of the effects of pioglitazone and rosiglitazone on de novo lipogenesis in type 2 diabetesJournal of Lipid Research, 2008
- Overproduction of VLDL 1 Driven by Hyperglycemia Is a Dominant Feature of Diabetic DyslipidemiaArteriosclerosis, Thrombosis, and Vascular Biology, 2005
- ThiazolidinedionesNew England Journal of Medicine, 2004
- Use and Abuse of HOMA ModelingDiabetes Care, 2004
- Thiazolidinediones and Blood Lipids in Type 2 DiabetesArteriosclerosis, Thrombosis, and Vascular Biology, 2003
- Ameliorated Hepatic Insulin Resistance Is Associated with Normalization of Microsomal Triglyceride Transfer Protein Expression and Reduction in Very Low Density Lipoprotein Assembly and Secretion in the Fructose-fed HamsterPublished by Elsevier BV ,2002
- MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trialThe Lancet, 2002
- Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.Diabetes Care, 2000
- Effects of Growth Hormone (GH) Replacement Therapy on Very Low Density Lipoprotein Apolipoprotein B100 Kinetics in Patients with Adult GH Deficiency: A Stable Isotope StudyJournal of Clinical Endocrinology & Metabolism, 1999
- Interpretation of measured red cell mass and plasma volume in adults: Expert Panel on Radionuclides of the International Council for Standardization in HaematologyBritish Journal of Haematology, 1995